Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Belzutifan (MK-6482) is a potential treatment for clear cell renal cell carcinoma (ccRCC). Belzutifan is an orally active and selective HIF-2α inhibitor (IC50: 9 nM). Belzutifan , as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 15,000 | |||
5 mg | 在庫あり | ¥ 35,500 | |||
10 mg | 在庫あり | ¥ 66,500 | |||
25 mg | 在庫あり | ¥ 112,000 | |||
50 mg | 在庫あり | ¥ 164,000 | |||
100 mg | 在庫あり | ¥ 226,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 39,000 |
説明 | Belzutifan (MK-6482) is a potential treatment for clear cell renal cell carcinoma (ccRCC). Belzutifan is an orally active and selective HIF-2α inhibitor (IC50: 9 nM). Belzutifan , as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. |
ターゲット&IC50 | HIF2α:9 nM |
In vitro | PT2977 effectively and dose-dependently decreased mRNA levels of human cyclin D1, a target gene regulated by HIF-2α. It leads to a rapid and dose-dependent reduction in EPO expression[1]. |
別名 | PT2977, MK-6482 |
分子量 | 383.34 |
分子式 | C17H12F3NO4S |
CAS No. | 1672668-24-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (130.43 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Belzutifan 1672668-24-4 Angiogenesis Chromatin/Epigenetic HIF Inhibitor PT 2977 PT2977 HIFs MK-6482 MK 6482 HIF/HIF Prolyl-Hydroxylase inhibit HIF-PH Hypoxia-inducible factors PT-2977 MK6482 inhibitor